Murphy Andrew J
Co-Chief Scientific Officer at REGN
- Sold, on record
- $62.4M
- Dollars the filings state
- Form 4 sales
- 15
- Latest Nov 17, 2026
- Form 144 notices
- 4
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- REGNREGENERON PHARMACEUTICALS, INC.Co-Chief Scientific Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale REGNRoutineNov 14, 2023 2023
Sold 6,492 shares at $799.17 ($5.2M)
Murphy Andrew J, EVP Research
10b5-1 planSold 9.8% of holdings ($52.7M position)59,421 shares left1.8x usual sizeFollows a Form 144Filing
- 2 Form 144 notice REGNNoticeDec 5, 2023 +21 days
Filed to sell 6,536 shares ($5.3M)
Murphy Andrew J, Officer
10b5-1 plan1.8x usual sizeFiling
- 3 Form 4 sale REGNRoutineDec 5, 2023 same day
Sold 6,536 shares at $817.44 ($5.3M)
Murphy Andrew J, EVP Research
10b5-1 planSold 9.9% of holdings ($53.9M position)59,421 shares left1.8x usual sizeFollows a Form 144Filing
- 4 Form 144 notice REGNNoticeMar 14, 2024 +100 days
Filed to sell 5,783 shares ($5.6M)
Murphy Andrew J, Officer
10b5-1 plan1.6x usual sizeFiling
- 5 Form 4 sale REGNRoutineMar 14, 2024 same day
Sold 5,783 shares at $956.47 ($5.5M)
Murphy Andrew J, EVP Research
10b5-1 planSold 10.7% of holdings ($51.7M position)48,306 shares left1.6x usual sizeFollows a Form 144Filing
- 6 Form 144 notice REGNNoticeAug 14, 2024 +153 days
Filed to sell 6,363 shares ($7.3M)
Murphy Andrew J, Officer
10b5-1 plan1.1x usual sizeFiling
- 7 Form 4 sale REGNRoutineAug 14, 2024 same day
Sold 6,363 shares at $1,153.15 ($7.3M)
Murphy Andrew J, EVP Research
10b5-1 planSold 11.6% of holdings ($63M position)48,306 shares left1.1x usual sizeFollows a Form 144Filing
- 8 Form 4 sale REGNRoutineNov 17, 2026 +825 days
Sold 5,011 shares at $957.76 ($4.8M)
Murphy Andrew J, Co-Chief Scientific Officer
10b5-1 planSold 9.7% of holdings ($49.6M position)46,779 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (19)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | Nov 18, 2026 | REGN | Co-Chief Scientific Officer | Form 4 sale | 5,011 | $4.8M | 9.7% | Routine | SEC |
| Aug 14, 2024 | Aug 15, 2024 | REGN | EVP Research | Form 4 sale | 6,363 | $7.3M | 11.6% | Routine | SEC |
| Aug 14, 2024 | Aug 14, 2024 | REGN | Officer | Form 144 notice | 6,363 | $7.3M | Notice | SEC | |
| Mar 14, 2024 | Mar 15, 2024 | REGN | EVP Research | Form 4 sale | 5,783 | $5.5M | 10.7% | Routine | SEC |
| Mar 14, 2024 | Mar 14, 2024 | REGN | Officer | Form 144 notice | 5,783 | $5.6M | Notice | SEC | |
| Dec 5, 2023 | Dec 6, 2023 | REGN | EVP Research | Form 4 sale | 6,536 | $5.3M | 9.9% | Routine | SEC |
| Dec 5, 2023 | Dec 5, 2023 | REGN | Officer | Form 144 notice | 6,536 | $5.3M | Notice | SEC | |
| Nov 14, 2023 | Nov 15, 2023 | REGN | EVP Research | Form 4 sale | 6,492 | $5.2M | 9.8% | Routine | SEC |
| Nov 14, 2023 | Nov 14, 2023 | REGN | Officer | Form 144 notice | 6,492 | $5.2M | Notice | SEC | |
| Nov 15, 2022 | Nov 16, 2022 | REGN | EVP Research | Form 4 sale | 3,720 | $2.7M | 6.1% | Plan not stated | SEC |
| Aug 16, 2022 | Aug 17, 2022 | REGN | EVP Research | Form 4 sale | 3,513 | $2.3M | 5.7% | Plan not stated | SEC |
| May 17, 2022 | May 18, 2022 | REGN | EVP Research | Form 4 sale | 3,543 | $2.4M | 5.7% | Plan not stated | SEC |
| Feb 15, 2022 | Feb 16, 2022 | REGN | EVP Research | Form 4 sale | 3,540 | $2.2M | 5.7% | Plan not stated | SEC |
| Dec 10, 2021 | Dec 10, 2021 | REGN | EVP Research | Form 4 sale | 7,122 | $4.7M | 10.7% | Plan not stated | SEC |
| Nov 16, 2021 | Nov 17, 2021 | REGN | EVP Research | Form 4 sale | 7,167 | $4.6M | 11.4% | Plan not stated | SEC |
| Nov 17, 2020 | Nov 18, 2020 | REGN | EVP Research | Form 4 sale | 6,628 | $3.6M | 12.3% | Plan not stated | SEC |
| Jul 14, 2020 | Jul 15, 2020 | REGN | EVP Research | Form 4 sale | 2,380 | $1.5M | 5.4% | Plan not stated | SEC |
| Jul 14, 2020 | Jul 15, 2020 | REGN | EVP Research | Form 4 sale | 11,929 | $7.5M | 21.2% | Plan not stated | SEC |
| Jan 27, 2020 | Jan 28, 2020 | REGN | EVP Research | Form 4 sale | 8,000 | $2.7M | 13.8% | Plan not stated | SEC |